Experiences with tumour necrosis factor-α inhibitors in patients with juvenile idiopathic arthritis

Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry

Krisztina Sevcic, Ilonka Orban, Valentin Brodszky, Anna Bazso, Z. Balogh, G. Poór, E. Kiss

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective. To report the efficacy and safety of TNF-α inhibitors (etanercept and adalimumab) in a cohort of patients with JIA treated in a single paediatric rheumatological centre. Methods. Patients with JIA under the age of 18 years, treated with TNF-α blockers at the Paediatric Rheumatologic Centre of the National Institute of Rheumatology and Physiotherapy (Budapest, Hungary) from 2002, were enrolled in an open, observational study. At baseline, patient and disease characteristics were registered. Disease activity was evaluated (before the start of the treatment and after every 3 months) according to the JIA core set of the ACR paediatric definition of improvement (ACR Pedi). Adverse events (AEs) were documented. Results. In all, 72 patients were evaluated. Mean (S.D.) age at onset was 5.5 (3.8) years, mean disease duration was 7.4 (3.9) years. All disease activity parameters improved significantly in the first 3 months of treatment. After 3 and 12 months of treatment, 88 and 76% of patients, respectively, achieved the criteria of the ACR Pedi 30. AEs were uncommon. After 12 months, >85% of patients continued the therapy. Conclusion. Anti-TNF-α agents (etanercept and adalimumab) are effective, safe and well tolerated in JIA patients. Extension of this study for a longer follow-up period and to the patients with JIA after the age of 18 years (with validated and comparable disease activity parameters) is needed to evaluate the long-term effectiveness and safety of the TNF-α inhibitors.

Original languageEnglish
Article numberker103
Pages (from-to)1337-1340
Number of pages4
JournalRheumatology
Volume50
Issue number7
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Juvenile Arthritis
Rheumatology
Registries
Tumor Necrosis Factor-alpha
Pediatrics
Safety
Hungary
Therapeutics
Age of Onset
Observational Studies

Keywords

  • Adalimumab
  • Anti-tumour necrosis factor-α
  • Biologic therapy registry
  • Etanercept
  • Inhibitors
  • JIA registry
  • Juvenile idiopathic arthritis
  • Therapy
  • Tumour necrosis factor-α

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Experiences with tumour necrosis factor-α inhibitors in patients with juvenile idiopathic arthritis : Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. / Sevcic, Krisztina; Orban, Ilonka; Brodszky, Valentin; Bazso, Anna; Balogh, Z.; Poór, G.; Kiss, E.

In: Rheumatology, Vol. 50, No. 7, ker103, 07.2011, p. 1337-1340.

Research output: Contribution to journalArticle

@article{0ea7011ebfa649ce92b4e2addaaabfab,
title = "Experiences with tumour necrosis factor-α inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry",
abstract = "Objective. To report the efficacy and safety of TNF-α inhibitors (etanercept and adalimumab) in a cohort of patients with JIA treated in a single paediatric rheumatological centre. Methods. Patients with JIA under the age of 18 years, treated with TNF-α blockers at the Paediatric Rheumatologic Centre of the National Institute of Rheumatology and Physiotherapy (Budapest, Hungary) from 2002, were enrolled in an open, observational study. At baseline, patient and disease characteristics were registered. Disease activity was evaluated (before the start of the treatment and after every 3 months) according to the JIA core set of the ACR paediatric definition of improvement (ACR Pedi). Adverse events (AEs) were documented. Results. In all, 72 patients were evaluated. Mean (S.D.) age at onset was 5.5 (3.8) years, mean disease duration was 7.4 (3.9) years. All disease activity parameters improved significantly in the first 3 months of treatment. After 3 and 12 months of treatment, 88 and 76{\%} of patients, respectively, achieved the criteria of the ACR Pedi 30. AEs were uncommon. After 12 months, >85{\%} of patients continued the therapy. Conclusion. Anti-TNF-α agents (etanercept and adalimumab) are effective, safe and well tolerated in JIA patients. Extension of this study for a longer follow-up period and to the patients with JIA after the age of 18 years (with validated and comparable disease activity parameters) is needed to evaluate the long-term effectiveness and safety of the TNF-α inhibitors.",
keywords = "Adalimumab, Anti-tumour necrosis factor-α, Biologic therapy registry, Etanercept, Inhibitors, JIA registry, Juvenile idiopathic arthritis, Therapy, Tumour necrosis factor-α",
author = "Krisztina Sevcic and Ilonka Orban and Valentin Brodszky and Anna Bazso and Z. Balogh and G. Po{\'o}r and E. Kiss",
year = "2011",
month = "7",
doi = "10.1093/rheumatology/ker103",
language = "English",
volume = "50",
pages = "1337--1340",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Experiences with tumour necrosis factor-α inhibitors in patients with juvenile idiopathic arthritis

T2 - Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry

AU - Sevcic, Krisztina

AU - Orban, Ilonka

AU - Brodszky, Valentin

AU - Bazso, Anna

AU - Balogh, Z.

AU - Poór, G.

AU - Kiss, E.

PY - 2011/7

Y1 - 2011/7

N2 - Objective. To report the efficacy and safety of TNF-α inhibitors (etanercept and adalimumab) in a cohort of patients with JIA treated in a single paediatric rheumatological centre. Methods. Patients with JIA under the age of 18 years, treated with TNF-α blockers at the Paediatric Rheumatologic Centre of the National Institute of Rheumatology and Physiotherapy (Budapest, Hungary) from 2002, were enrolled in an open, observational study. At baseline, patient and disease characteristics were registered. Disease activity was evaluated (before the start of the treatment and after every 3 months) according to the JIA core set of the ACR paediatric definition of improvement (ACR Pedi). Adverse events (AEs) were documented. Results. In all, 72 patients were evaluated. Mean (S.D.) age at onset was 5.5 (3.8) years, mean disease duration was 7.4 (3.9) years. All disease activity parameters improved significantly in the first 3 months of treatment. After 3 and 12 months of treatment, 88 and 76% of patients, respectively, achieved the criteria of the ACR Pedi 30. AEs were uncommon. After 12 months, >85% of patients continued the therapy. Conclusion. Anti-TNF-α agents (etanercept and adalimumab) are effective, safe and well tolerated in JIA patients. Extension of this study for a longer follow-up period and to the patients with JIA after the age of 18 years (with validated and comparable disease activity parameters) is needed to evaluate the long-term effectiveness and safety of the TNF-α inhibitors.

AB - Objective. To report the efficacy and safety of TNF-α inhibitors (etanercept and adalimumab) in a cohort of patients with JIA treated in a single paediatric rheumatological centre. Methods. Patients with JIA under the age of 18 years, treated with TNF-α blockers at the Paediatric Rheumatologic Centre of the National Institute of Rheumatology and Physiotherapy (Budapest, Hungary) from 2002, were enrolled in an open, observational study. At baseline, patient and disease characteristics were registered. Disease activity was evaluated (before the start of the treatment and after every 3 months) according to the JIA core set of the ACR paediatric definition of improvement (ACR Pedi). Adverse events (AEs) were documented. Results. In all, 72 patients were evaluated. Mean (S.D.) age at onset was 5.5 (3.8) years, mean disease duration was 7.4 (3.9) years. All disease activity parameters improved significantly in the first 3 months of treatment. After 3 and 12 months of treatment, 88 and 76% of patients, respectively, achieved the criteria of the ACR Pedi 30. AEs were uncommon. After 12 months, >85% of patients continued the therapy. Conclusion. Anti-TNF-α agents (etanercept and adalimumab) are effective, safe and well tolerated in JIA patients. Extension of this study for a longer follow-up period and to the patients with JIA after the age of 18 years (with validated and comparable disease activity parameters) is needed to evaluate the long-term effectiveness and safety of the TNF-α inhibitors.

KW - Adalimumab

KW - Anti-tumour necrosis factor-α

KW - Biologic therapy registry

KW - Etanercept

KW - Inhibitors

KW - JIA registry

KW - Juvenile idiopathic arthritis

KW - Therapy

KW - Tumour necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=79959486057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959486057&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ker103

DO - 10.1093/rheumatology/ker103

M3 - Article

VL - 50

SP - 1337

EP - 1340

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 7

M1 - ker103

ER -